Bufalin enhances TRAIL-induced apoptosis by redistributing death receptors in lipid rafts in breast cancer cells

Anti-Cancer Drugs

Volumn 25, Issue 6, 2014, Pages 683-689

  Yan, Shunchao ^a   Qu, Xiujuan ^a   Xu, Ling ^a   Che, Xiaofang ^a   Ma, Yanju ^a   Zhang, Lingyun ^a   Teng, Yuee ^a   Zou, Huawei ^a   Liu, Yunpeng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Bufalin; Death receptor; Lipid raft; TRAIL

Indexed keywords

BUFALIN; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; METHYL BETA CYCLODEXTRIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN DERIVATIVE; BUFADIENOLIDE DERIVATIVE; CHOLESTEROL; METHYL-BETA-CYCLODEXTRIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE PHASE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; LIPID RAFT; MCF 7 CELL LINE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; BREAST TUMOR; CELL MEMBRANE; DRUG EFFECTS; FEMALE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA-CYCLODEXTRINS; BREAST NEOPLASMS; BUFANOLIDES; CELL LINE, TUMOR; CHOLESTEROL; FEMALE; HUMANS; MEMBRANE MICRODOMAINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84901616419     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000095     Document Type: Article

References (27)

1. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 2004; 9:617-632. (Pubitemid 39546403)
2. Bernard-Marty C, Lebrun F, Awada A, Piccart MJ. Monoclonal antibodybased targeted therapy in breast cancer: Current status and future directions. Drugs 2006; 66:1577-1591. (Pubitemid 44373744)
3. Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced nonsmall cell lung cancer. Lung Cancer 2008; 61:82-90.
4. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007; 13:6187-6194. (Pubitemid 350075080)
5. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999; 59:734-741. (Pubitemid 29076075)
6. Yan S, Qu X, Xu C, Zhu Z, Zhang L, Xu L, et al. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAILinduced apoptosis in breast cancer cells. J Cancer Res Clin Oncol 2012; 138:1279-1289.
7. MacFarlane M. TRAIL-induced signalling and apoptosis. Toxicol Lett 2003; 139:89-97. (Pubitemid 36298966)
8. Rajendran L, Simons K. Lipid rafts and membrane dynamics. J Cell Sci 2005; 118:1099-1102. (Pubitemid 40528680)
9. Scheel-Toellner D, Wang K, Assi LK, Webb PR, Craddock RM, Salmon M, et al. Clustering of death receptors in lipid rafts initiates neutrophil spontaneous apoptosis. Biochem Soc Trans 2004; 32:679-681. (Pubitemid 39524351)
10. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005; 12:228-237. (Pubitemid 40315182)
11. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2:420-430. (Pubitemid 37328939)
12. Psahoulia FH, Drosopoulos KG, Doubravska L, Andera L, Pintzas A. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther 2007; 6:2591-2599. (Pubitemid 47480425)
13. Xu L, Qu X, Zhang Y, Hu X, Yang X, Hou K, et al. Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts. FEBS Lett 2009; 583:943-948.
14. Krenn L, Kopp B. Bufadienolides from animal and plant sources. Phytochemistry 1998; 48:1-29. (Pubitemid 28242374)
15. Qi F, Li A, Inagaki Y, Kokudo N, Tamura S, Nakata M, et al. Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. Int Immunopharmacol 2011; 11:342-349.
16. Dong Y, Yin S, Li J, Jiang C, Ye M, Hu H. Bufadienolide compounds sensitize human breast cancer cells to TRAIL-induced apoptosis via inhibition of STAT3/Mcl-1 pathway. Apoptosis 2011; 16:394-403.
17. Vial C, Evans RJ. Disruption of lipid rafts inhibits P2X1 receptor-mediated currents and arterial vasoconstriction. J Biol Chem 2005; 280: 30705-30711. (Pubitemid 41291799)
18. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5:157-163. (Pubitemid 29068521)
19. Roth W, Isenmann S, Naumann U, Kü gler S, Bä hr M, Dichgans J, et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 1999; 265:479-483.
20. Lee KY, Park JS, Jee YK, Rosen GD. Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation. Exp Mol Med 2002; 34:462-468. (Pubitemid 36114364)
21. Fulda S, Debatin KM. Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Eur J Cancer 2005; 41:786-798. (Pubitemid 40342561)
22. Yodkeeree S, Sung B, Limtrakul P, Aggarwal BB. Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species. Cancer Res 2009; 69:6581-6589.
23. Mé rino D, Lalaoui N, Morizot A, Solary E, Micheau O. TRAIL in cancer therapy: Present and future challenges. Expert Opin Ther Targets 2007; 11:1299-1314.
24. Lim SC, Duong HQ, Choi JE, Lee TB, Kang JH, Oh SH, Han SI. Lipid raftdependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells. Carcinogenesis 2011; 32:723-731.
25. Scheel-Toellner D, Wang K, Singh R, Majeed S, Raza K, Curnow SJ, et al. The death-inducing signaling complex is recruited to lipid rafts in Fas-induced apoptosis. Biochem Biophys Res Commun 2002; 297:876-879. (Pubitemid 35230331)
26. Vanoosten RL, Moore JM, Ludwig AT, Griffith TS. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol Ther 2005; 11:542-552. (Pubitemid 40353112)
27. Xu L, Qu X, Luo Y, Zhang Y, Liu J, Qu J, et al. Epirubicin enhances TRAIL-induced apoptosis in gastric cancer cells by promoting death receptor clustering in lipid rafts. Mol Med Rep 2011; 4:407-411..